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Fig 2. Rosacea, patient 1. Twelve hours after application
of brimonidine tartrate to forehead, cheeks, nose, and
chin. Erythema is present in all of the areas where the
medication was applied.
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e38 Lettersalpha-adrenergic agonist nasal sprays (eg, oxymetazo-
line and xylometazoline).4 This reaction directly
opposes the goal of therapy.
Counseling about the potential for worsening
erythema, use of a test area, and limiting use to
special occasions may bewarranted. Viewing images
of this adverse reaction prior to use may alleviate
patient distress.
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cyclosporine and isotretinoin
To the Editor: Acne fulminans (AF) is a rare and very
severe form of acne characterized by the sudden
onset of painful, ulcerative pustules and associated
systemic symptoms. Recommended treatment is a
combination of oral steroids and isotretinoin. We
report the case of a male patient with poor response
to this treatment who was successfully treated with
the combination of oral cyclosporine and
isotretinoin.
A 15-year-old white male patient with severe acne
flare was referred to our hospital. Diagnosis was
acne vulgaris for the past 2 years, treated with topical
antibiotics. Six months before the consultation, the
lesions worsened and a diagnosis of acne conglobata
was made. He was treated with isotretinoin 20 mg/
day and prednisone 15 mg/day, but there was no
clinical improvement. Isotretinoin dosage was
increased to 30 mg/day, but 3 weeks later multiple
reddish papulonodular and ulcerated lesions with
hemorrhagic crusts suddenly developed on his face,
neck, and trunk. The lesions were painful, and
arthralgias and temperature up to 398C were noted
(Fig 1). Abnormal laboratory findings included
elevated C-reactive protein levels (5 mg/dL; normal
\ 1 mg/dL) and leukocytosis (15,700 cells/mm3)
with neutrophilia (68.8%). AF was diagnosed, and
treatment with prednisone 60 mg/day and isotreti-
noin 20mg/day was initially successful. Nevertheless
progressive worsening was observed in the
following weeks while prednisone was tapered
and isotretinoin increased to 30 mg/day. He was
treated with potassium permanganate baths and
topical antibiotics. Oral cyclosporine 5 mg/kg/day
plus isotretinoin 30 mg/day was initiated and
systemic steroids were stopped. After a few weeks,
Fig 2. Acne fulminans. Complete resolution of the
inflammatory lesions with residual scarring after treatment
with cyclosporine and isotretinoin.
Fig 1. Acne fulminans. Initial presentation with draining
pustules and crusted papules and nodules on the back.
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Letters e39the lesions improved, and 4 months later, cyclo-
sporinewas discontinued. A total dose of isotretinoin
100 mg/kg could be completed, and he presented an
almost complete resolution of the inflammatory
lesions with some residual scarring (Fig 2). No
significant side effects or laboratory abnormalities
were observed during treatment.
AF is a rare condition that is considered the most
severe form of acne. It is characterized by a sudden
onset of ulcerative, crusty, painful lesions. Most
patients are young teenagers with previous mild to
moderate acne. It is considered a severe inflamma-
tory diseasewith abscess formation and hemorrhagic
crusts accompanied by high temperature, asthenia,
anorexia, and often asymmetric polyarthralgias.1
In this case, laboratory findings showed an
intense neutrophilic leucocytosis and elevation of
erythrocyte sedimentation rate and C-reactive
protein. The etiology of AF is appears to be
multifactorial.2 The diagnosis is usually clinical. The
differential diagnosis includes other disorders such
as PAPA3 syndrome and SAPHO syndrome.4Oral antibiotics are usually ineffective. The
combination of oral isotretinoin and systemic
corticosteroids is the treatment of choice,1 but
recurrences are not unusual when steroid dose is
tapered. We have found only 1 report describing a
good response of AF to a combination of cyclo-
sporine and prednisolone.5 To our knowledge this is
the first report showing a good response to
cyclosporine combined with isotretinoin. Because
this regimen has a very good short-term safety
profile (particularly in young persons), it can be an
alternative in patients with AF when systemic
steroids are either ineffective or contraindicated.
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Complete pathologic response after
neoadjuvant treatment with vemurafenib for
malignant melanoma
To the Editor: Invasive melanoma on the left arm was
diagnosed in a 32-year-old male patient. The initial
diagnosis wasmade by skin biopsy, which revealed a
nonulcerated melanoma of 3 mm depth. The patient
underwent reexcision and sentinel lymph node
